SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for risk assessment, prophylaxis, diagnosis, and treatment of venous thromboembolism in cancer patients, including catheter-related thrombosis.
Comprehensive management of central venous access device-related thrombosis including diagnosis, treatment, catheter management decisions, upper extremity DVT, patient education, monitoring, and follow-up.
Management of cancer-associated VTE in special populations including brain tumors, thrombocytopenia, renal impairment, GI/GU cancers, recurrent VTE on anticoagulation, incidental and subsegmental PE, and IVC filter indications.
Complete treatment protocols for cancer-associated VTE including LMWH dosing, DOAC regimens (rivaroxaban, edoxaban, apixaban), warfarin considerations, duration of anticoagulation, and landmark trial data from SELECT-D, HOKUSAI-VTE Cancer, ADAM-VTE, and CARAVAGGIO.
Evidence-based recommendations for VTE prophylaxis in ambulatory, hospitalized, and surgical cancer patients, including CVAD-related thrombosis prevention, with complete dosing tables and key trial data.
Pathophysiology of cancer-associated thrombosis, Virchow's triad in malignancy, and validated VTE risk assessment models including the Khorana score, Vienna CATS score, PROTECHT score, and ONKOTEV score with complete scoring tables.